Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
株式のランク #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
株価
$1.81
最終同期: 2026-08-21
時価総額
$77.00M
変化(1日)
1.30%
変化(1年)
-23.63%
US
取引 Annovis Bio, Inc. (ANVS)

カテゴリー

Annovis Bio, Inc.(ANVS)の配当利回りの履歴
Annovis Bio, Inc.(銘柄コード: ANVS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Annovis Bio, Inc.(ANVS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)